Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan;
In Vivo. 2021 Jan-Feb;35(1):203-213. doi: 10.21873/invivo.12249.
BACKGROUND/AIM: At present, there are no biomarkers to predict the effects of molecular targeted drugs in patients with CRC with liver metastasis. Thus, we performed this study to explore potential biomarkers for these patients.
We obtained cancer tissue specimens from liver metastasis-bearing CRC patients who received the following preoperative neoadjuvant chemotherapies with molecular targeted drugs: i) no therapy (n=3), ii) 5-FU+oxaliplatin+anti-EGFR (n=3), iii) and 5-FU+oxaliplatin+anti-VEGF (n=3).
We investigated the RNA expression of 84 genes related to cancer drug resistance using an RT-PCR array. The MYC gene was the only gene that was significantly up-regulated in CRC tissue specimens from anti-EGFR group in comparison to the anti-VEGF group.
MYC up-regulation in the primary CRC tissues may be a potentially useful biomarker for selecting anti-EGFR combination therapy in neoadjuvant chemotherapy for CRC with liver metastasis.
背景/目的：目前，尚无生物标志物可预测结直肠癌伴肝转移患者接受分子靶向药物治疗的效果。因此，我们进行了这项研究，以探索这些患者的潜在生物标志物。
我们从接受以下术前新辅助化疗联合分子靶向药物治疗的肝转移结直肠癌患者中获得了肿瘤组织标本：i）无治疗（n=3），ii）5-FU+奥沙利铂+抗 EGFR（n=3），iii）5-FU+奥沙利铂+抗 VEGF（n=3）。
我们使用 RT-PCR 阵列研究了与癌症药物耐药性相关的 84 个基因的 RNA 表达。与抗 VEGF 组相比，抗 EGFR 组结直肠癌组织中 MYC 基因显著上调。
原发性 CRC 组织中 MYC 的上调可能是结直肠癌伴肝转移新辅助化疗中选择抗 EGFR 联合治疗的一个有潜在用途的生物标志物。
